Pemphigus vulgaris patients with exclusive oral involvement (OPV) treated with conventional immunosuppressive therapy may be non-responders or experience severe side effects and/or relapses. In such cases, rituximab could be used as an adjuvant in recalcitrant OPV patients.
The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris / Fortuna, G.; Calabria, E.; Ruoppo, E.; Adamo, D.; Aria, M.; Amato, M.; Mignogna, M. D.. - In: JOURNAL OF ORAL PATHOLOGY & MEDICINE. - ISSN 0904-2512. - (2020). [10.1111/jop.12951]
The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris
Fortuna G.;Calabria E.;Ruoppo E.;Aria M.;Mignogna M. D.
2020
Abstract
Pemphigus vulgaris patients with exclusive oral involvement (OPV) treated with conventional immunosuppressive therapy may be non-responders or experience severe side effects and/or relapses. In such cases, rituximab could be used as an adjuvant in recalcitrant OPV patients.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
